Manufacturer record

Rivpra Formulation Pvt.Ltd.Plot No.8: regulatory record

Last checked 20 September 2026. Source: CDSCO monthly NSQ alerts and state drug-testing laboratories

5 batches manufactured by Rivpra Formulation Pvt.Ltd.Plot No.8 (Uttarakhand) were declared Not of Standard Quality between September 2025 and July 2026. Records are batch-specific findings by government laboratories as published in CDSCO's monthly alerts; where a company has stated that a flagged batch was counterfeit, that statement is noted when reported.

Records by type

5 records linked to Rivpra Formulation Pvt.Ltd.Plot No.8 in the datasets we hold. A zero means nothing is on record in those datasets, not that nothing ever happened. What the labels mean.

0Banned or prohibited
0Recalled or suspended
5Failed a lab test
0Regulatory notice
Primary government sourceTier 1: government primary source

CDSCO drug alerts: Not of Standard Quality and spurious drugs

CDSCO · CDSCO monthly NSQ alerts, Sep 2025 to Jul 2026

View original document

Scope. A company appearing here is not a finding that its products are unsafe. Regulatory actions can apply to one batch, one formulation, one period or one state. Always check the linked government document for the current position, and tell us if something is out of date. How we label records.

5
NSQ batches since 2025
4
Products affected
Other
Most common failure
Jul 2026
Latest alert

Flagged batches per year

2025 · 22026 · 3

All flagged batches

Product Batch Reason declared NSQ Tested by Alert
Glimepiride Tablets IP 4mg T2512152Mfg 2025-12 · Exp 2027-11 Does not conform to IP Standards with respect to Dissolution TestDissolution Food & Drugs Laboratory Bambolim, GoaState lab Jul 2026
Ambroxol Hydrochloride, Guaiphenesin & Terbutaline Sulphate Syrup L-2508007Mfg 2025-08 · Exp 2027-07 The sample does not conform to claim as per Patent and Proprietary in respect to the Test of Total fungal countOther RDTL, ChandigarhCDSCO lab Feb 2026
Ambroxol Hydrochloride, Guaiphenesin & Terbutaline Sulphate Syrup L-2508003Mfg 2025-08 · Exp 2027-07 The sample does not conform to claim as per Patent and Proprietary in respect to the Test of Total fungal countOther RDTL, ChandigarhCDSCO lab Feb 2026
Ciprofloxacin Tablets U.S.P. 500 mg.. T-2408090Mfg 2024-08 · Exp 2026-07 The sample does not conform to claim as per U.S.P. with respect to the test for "Dissolution" of Ciprofloxacin.Dissolution RDTL, GuwahatiCDSCO lab Nov 2025
CLOPIMEN-75 Clopidogrel Tablets IP 75 mg T-2405321Mfg 2024-05 · Exp 2026-04 sample received does not conform to I.P. 2022 for the reason stated under description and with respect to the tests for Related substances" and "Assay.Assay CDTL, MumbaiCDSCO lab Sep 2025

Right of reply. Manufacturers may submit a response or a laboratory re-test result; it is published unedited alongside this record. Submit a response.